Roberto Chiletti, Sophie H. Fincher, Stephen B. Horton, Giles J. Peek, Paul Checchia, Warwick Butt
Royal Children’s Hospital and University of Melbourne. University of Florida. Texas Children’s Hospital and the Baylor College of Medicine.
Australia and United States
Canadian Journal of Cardiology
Can J Cardiol 2024;
DOI: 10.1016/j.cjca.2024.12.027
Abstract
Nitric oxide (NO) was proclaimed the 1992 “molecule of the year” by Culotta in Science magazine because of its importance in neuroscience, physiology and immunology. Inhaled NO has been in clinical use for over 35 years to decrease pulmonary hypertension and improve oxygenation. Over the last 20 years there has been much research to understand the role of nitric oxide on cell surface receptors, mitochondria, and intracellular processes which involve calcium and superoxide radicals. This research has shown that, irrespective of the cause, NO has a major role in the systemic inflammatory response syndrome (SIRS) and ischaemia-reperfusion injury (IRI).1 More recent clinical research has focused on NO use in patients undergoing cardiopulmonary bypass and receiving extracorporeal life support, with some centres incorporating nitric oxide into sweep gas as part of routine practice. This article reviews NO pathways in humans, the biological effects of NO, the interplay between nitric oxide and red blood cells, and animal and human studies on the effects of exogenously administered NO.
Category
Medical Therapy. Efficacy or Lack of Efficacy
Medical Therapy. Adverse Effects or Lack of Adverse Effects
Medical Therapy. Pharmacokinetics and Pharmacology
Review Articles Concerning Pulmonary Vascular Disease
Age Focus: Pediatric Pulmonary Vascular Disease
Fresh or Filed Publication: Fresh (PHresh). Less than 1-2 years since publication
Article Access
Free PDF File or Full Text Article Available Through PubMed or DOI: No